1. Anti‐tumour potential of PD‐L1/PD‐1 post‐translational modifications.
- Author
-
Zhou, Shimeng, Zhu, Jinfeng, Xu, Jingwei, Gu, Bingzi, Zhao, Qiao, Luo, Congzhou, Gao, Zhoufeng, Chin, Y. Eugene, and Cheng, Xiaju
- Subjects
POST-translational modification ,PROGRAMMED cell death 1 receptors ,IMMUNE checkpoint proteins ,DEATH receptors ,CELLULAR signal transduction ,T cell receptors - Abstract
The immune checkpoint programmed death receptor 1 (PD‐1) and programmed death ligand 1 (PD‐L1) are biologically important immunosuppressive molecules, and the PD‐L1/PD‐1‐mediated signalling pathway is currently considered one of the main mechanisms of tumour escape immune surveillance. PD‐L1 is highly expressed on the cytomembrane of tumour cell and binds to PD‐1 receptor of activated T cells. This interaction activates PD‐L1/PD‐1 downstream signal transduction, inhibiting T cells anti‐tumour activity. Therefore, inhibitors of PD‐L1/PD‐1 activation, showing significant efficacy in some types of tumours, have been widely approved in clinical tumour therapy. Recent research on PD‐L1/PD‐1 signalling pathway regulation has shown post‐translational modifications (PTMs) form of PD‐L1 or PD‐1, including glycosylation, ubiquitination, phosphorylation, and acetylation, which may play an important role in PD‐L1/PD‐1 signalling pathway regulation and anti‐tumour function of T cells. In this review, we focused on PTMs of PD‐L1/PD‐1 research and potential applications in tumour immunotherapy. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF